Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (MEL53)

This study has suspended participant recruitment.
(Study staff out on medical leave)
Sponsor:
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia
ClinicalTrials.gov Identifier:
NCT01264731
First received: December 20, 2010
Last updated: September 19, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: June 2015
  Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)